A Phase III-IV, Multicenter Open Label Trial of Arimidex Alone Versus Arimidex Plus Bisphosphonates in Postmenopausal Patients With Early, Endocrine Positive Breast Cancer.
N/A
18 Years
80 Years
18 Years
80 Years
Not Enrolling
Female
Breast Cancer, Bone Density
Female
Breast Cancer, Bone Density
Trial Information
A Phase III-IV, Multicenter Open Label Trial of Arimidex Alone Versus Arimidex Plus Bisphosphonates in Postmenopausal Patients With Early, Endocrine Positive Breast Cancer.
Inclusion Criteria:
- Postmenopausal women
- ER and or PgR positive breast cancer
- Completed Surgery and =/- chemotherapy
Exclusion Criteria:
- metastases
- history of fractures
- HRT or SERMs
- Liver or kidney disfunction
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Authority:
Greece: National Organization of Medicines
Study ID:
D5392L0027
NCT ID:
NCT00809484
Start Date:
May 2004
Completion Date:
February 2007
Related Keywords:
- Breast Cancer
- Bone Density
- Arimidex
- Bone Mineral density
- Bisphosphonates
- Aromatase Inhibitors
- Breast Neoplasms
Name | Location |
|---|
